Who
Alan B. Sandler
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Revolution Medicines; Chief Medical Officer, ALX Oncology Holdings; Director, Elevation Oncology; Chief Medical Officer, Mirati Therapeutics; Head of Global Dev., Oncology, Zai Lab.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.4M
- Companies
- 5
- Companies where not an officer
- 1
- First trade
- 1 Apr 2021
- Last trade
- 29 Sep 2026
- Last filed
- 1 Oct 2026
Companies traded
Activity over time
1 Sep – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Sep 2026filed 1 Oct 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $353K6,000 at $58.84 | filing |
| 29 Sep 2026filed 1 Oct 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $442K2,200 at $200.82 | filing |
| 29 Sep 2026filed 1 Oct 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $325K1,609 at $201.72 | filing |
| 29 Sep 2026filed 1 Oct 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $203K1,000 at $202.81 | filing |
| 29 Sep 2026filed 1 Oct 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $244K1,199 at $203.91 | filing |
| 29 Sep 2026filed 1 Oct 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $62K301 at $204.72 | filing |
| 29 Sep 2026filed 1 Oct 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,000 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $9755 at $194.96 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $67K336 at $199.30 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $9755 at $194.96 | filing |
| 16 Sep 2026filed 18 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $67K336 at $199.30 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,100 at $0.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,100 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —55,000 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —35,000 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —35,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 11 Apr 2025filed 15 Apr 2025 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 21 Jan 2025filed 23 Jan 2025 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 18 Nov 2024filed 19 Nov 2024 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
News
Revolution Medicines' Pancreatic Cancer Drug Gets Positive EU ReviewRVMD · finanzen.ch · 15 Oct 2026Revolution Medicines (NASDAQ:RVMD) Shares Up 3.4% on Analyst UpgradeRVMD · themarketsdaily.com · 14 Oct 2026Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' DaraxonrasibRVMD · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Alan B. Sandler; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.